litlas
Log inCreate account

Shridar Ganesan

Active 1990–2025

113
Papers
18,921
Citations
64
h-index
108
i10-index

Citations

Citations per year for Shridar Ganesan1982: 1 citations1990: 2 citations1991: 2 citations1992: 5 citations1993: 5 citations1994: 3 citations1995: 2 citations1996: 10 citations1997: 11 citations1998: 16 citations1999: 11 citations2000: 25 citations2001: 58 citations2002: 79 citations2003: 98 citations2004: 106 citations2005: 109 citations2006: 119 citations2007: 149 citations2008: 139 citations2009: 156 citations2010: 212 citations2011: 246 citations2012: 196 citations2013: 237 citations2014: 246 citations2015: 245 citations2016: 256 citations2017: 247 citations2018: 300 citations2019: 725 citations2020: 772 citations2021: 814 citations2022: 717 citations2023: 571 citations2024: 752 citations2025: 404 citations2026: 27 citations1983–1989: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,284 citing papers, 30.1% of this breakdownChina: 1,305 citing papers, 12% of this breakdownUnited Kingdom: 782 citing papers, 7.2% of this breakdownItaly: 411 citing papers, 3.8% of this breakdownGermany: 410 citing papers, 3.7% of this breakdownFrance: 370 citing papers, 3.4% of this breakdownCanada: 363 citing papers, 3.3% of this breakdownIndia: 294 citing papers, 2.7% of this breakdownJapan: 293 citing papers, 2.7% of this breakdownNetherlands: 292 citing papers, 2.7% of this breakdownSpain: 255 citing papers, 2.3% of this breakdownAustralia: 247 citing papers, 2.3% of this breakdown
0%30.1%Other 23.8%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology44%
  • Medicine34.3%
  • Computer Science15.7%
  • Immunology and Microbiology2.1%
  • Agricultural and Biological Sciences1.3%
  • Engineering0.8%
  • Other1.8%

Topics

  • DNA Repair Mechanisms7%
  • AI in cancer detection5.5%
  • PARP inhibition in cancer therapy3.8%
  • Radiomics and Machine Learning in Medical Imaging3.2%
  • CRISPR and Genetic Engineering3.1%
  • Cancer Genomics and Diagnostics2.8%
  • Other74.6%

Coauthors

All papers

Open in search
  1. Understanding and overcoming resistance to PARP inhibitors in cancer therapy

    Authors: Mariana Paes Dias, Sarah C. Moser, Shridar Ganesan, Jos Jonkers - Nature Reviews Clinical Oncology 2021 cited by 487

  2. Accurate and reproducible invasive breast cancer detection in whole-slide images: A Deep Learning approach for quantifying tumor extent

    Authors: Ángel Cruz-Roa, Hannah Gilmore, Ajay Basavanhally, Michael D. Feldman, Shridar Ganesan, Natalie Shih, John Tomaszewski, Fabio A. González, Anant Madabhushi - Scientific Reports 2017 cited by 542

  3. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers

    Authors: Matteo Palmeri, Janice M. Mehnert, Ann W. Silk, Salma K. Jabbour, Shridar Ganesan, Pallvi Popli, Gregory Riedlinger, Ryan D. Stephenson, Alexandre Buckley de Meritens, Aliza Leiser, Tina Mayer, Nancy Chan, Kristen Spencer, Eugenia Girda, Jyoti Malhotra, Timothy A. Chan, Vivek Subbiah, Roman Groisberg - ESMO Open 2021 cited by 353

  4. Automatic detection of invasive ductal carcinoma in whole slide images with convolutional neural networks

    Authors: Angel Cruz-Roa, Ajay Basavanhally, Fabio A. González, Hannah Gilmore, Michael D. Feldman, Shridar Ganesan, Natalie Shih, John Tomaszewski, Anant Madabhushi - SPIE, Digital Pathology 2014 cited by 588

  5. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion

    Authors: Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal I. Lindeman, Kathleen Moore, Shridar Ganesan, Christine M. Lovly, Jane Perlmutter, Stacy W. Gray, Jimmy Hwang, Christopher Lieu, Fabrice André, Nilofer Azad, Mitesh Borad, Laura Tafe, Hans Messersmith, Mark Robson, Funda Meric-Bernstam - Journal of Clinical Oncology 2022 cited by 249

  6. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

    Authors: Peter Bouwman, Amal Aly, José Miguel Escandell, Mark Pieterse, Jiřina Bártková, Hanneke van der Gulden, Sanne Hiddingh, Maria Thanasoula, Atul Kulkarni, Qifeng Yang, Bruce G. Haffty, Johanna Tommiska, Carl Blomqvist, Ronny Drapkin, David J. Adams, Heli Nevanlinna, Jiří Bártek, Madalena Tarsounas, Shridar Ganesan, Jos Jonkers - Nature Structural & Molecular Biology 2010 cited by 1,021

  7. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

    Authors: Christof C. Smith, Kathryn E. Beckermann, Dante S. Bortone, Aguirre A. de Cubas, Lisa M. Bixby, Samuel Lee, Anshuman Panda, Shridar Ganesan, Gyan Bhanot, Eric Wallen, Matthew I. Milowsky, William Y. Kim, W. Kimryn Rathmell, Ronald Swanstrom, Joel S. Parker, Jonathan S. Serody, Sara R. Selitsky, Benjamin G. Vincent - Journal of Clinical Investigation 2018 cited by 310

  8. Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

    Authors: Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly, James H. Doroshow, Aaron Cranston, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Shridar Ganesan, Piet Borst, Jos Jonkers, Sven Rottenberg - Cancer Discovery 2012 cited by 515

  9. Emerging strategies for treating metastasis

    Authors: Mark Esposito, Shridar Ganesan, Yibin Kang - Nature Cancer 2021 cited by 164

  10. Nuclear shape and orientation features from H&E images predict survival in early-stage estrogen receptor-positive breast cancers

    Authors: Cheng Lu, David Romo‐Bucheli, Xiangxue Wang, Andrew Janowczyk, Shridar Ganesan, Hannah Gilmore, David L. Rimm, Anant Madabhushi - Laboratory Investigation 2018 cited by 164

  11. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer

    Authors: Mridula George, Sadaf Qureshi, Coral Omene, Deborah Toppmeyer, Shridar Ganesan - Frontiers in Oncology 2021 cited by 149

  12. Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer

    Authors: Jon Whitney, Germán Corredor, Andrew Janowczyk, Shridar Ganesan, Scott Doyle, John Tomaszewski, Michael D. Feldman, Hannah Gilmore, Anant Madabhushi - BMC Cancer 2018 cited by 112

  13. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma

    Authors: Anshuman Panda, Aguirre A. de Cubas, Mark N. Stein, Gregory Riedlinger, Joshua Kra, Tina Mayer, Christof C. Smith, Benjamin G. Vincent, Jonathan S. Serody, Kathryn E. Beckermann, Shridar Ganesan, Gyan Bhanot, W. Kimryn Rathmell - JCI Insight 2018 cited by 179

  14. High-throughput adaptive sampling for whole-slide histopathology image analysis (HASHI) via convolutional neural networks: Application to invasive breast cancer detection

    Authors: Ángel Cruz-Roa, Hannah Gilmore, Ajay Basavanhally, Michael D. Feldman, Shridar Ganesan, Natalie Shih, John Tomaszewski, Anant Madabhushi, Fabio A. González - PLoS ONE 2018 cited by 151

  15. Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

    Authors: Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij‐de Haas, Gregory Riedlinger, Hua Zhu Ke, Russell W. Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Hui‐Ling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte‐Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou‐Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jiménez, Shridar Ganesan, Lodewyk F.A. Wessels, Jos Jonkers - Nature 2022 cited by 130

  16. Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response

    Authors: Laura Poillet-Perez, Daniel W. Sharp, Yang Yang, Saurabh V. Laddha, Maria Ibrahim, Praveen K. Bommareddy, Zhixian Hu, Joshua A Vieth, Michael Haas, Marcus Bosenberg, Joshua D. Rabinowitz, Jian Cao, Jun‐Lin Guan, Shridar Ganesan, Chang S. Chan, Janice M. Mehnert, Edmund C. Lattime, Eileen White - Nature Cancer 2020 cited by 111

  17. Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

    Authors: Daniel P. Silver, Andrea L. Richardson, Aron C. Eklund, Zhigang C. Wang, Zoltán Szállási, Qiyuan Li, N. Juul, Chee-Onn Leong, Diana Calogrias, Ayodele Buraimoh, Aquila Fatima, Rebecca Gelman, Paula D. Ryan, Nadine Tung, Arcangela De Nicolo, Shridar Ganesan, Alexander Miron, Christian Colin, Dennis C. Sgroi, Leif W. Ellisen, Eric P. Winer, Judy E. Garber - Journal of Clinical Oncology 2010 cited by 984

  18. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer

    Authors: Janice M. Mehnert, Anshuman Panda, Judy Zhong, Kim M. Hirshfield, Sherri Damare, Katherine Lane, Levi Sokol, Mark N. Stein, Lorna Rodriguez-Rodriquez, Howard L. Kaufman, Siraj M. Ali, Jeffrey S. Ross, Dean C. Pavlick, Gyan Bhanot, Eileen White, Robert S. DiPaola, Ann Lovell, Jonathan D. Cheng, Shridar Ganesan - Journal of Clinical Investigation 2016 cited by 385

  19. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment

    Authors: Verónica Rojas, Kim M. Hirshfield, Shridar Ganesan, Lorna Rodríguez-Rodríguez - International Journal of Molecular Sciences 2016 cited by 262

  20. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer

    Authors: Anshuman Panda, Janice M. Mehnert, Kim M. Hirshfield, Gregory Riedlinger, Sherri Damare, Tracie Saunders, Michael P. Kane, Levi Sokol, Mark N. Stein, Elizabeth Poplin, Lorna Rodríguez-Rodríguez, Ann W. Silk, Joseph Aisner, Nancy Chan, Jyoti Malhotra, Melissa Frankel, Howard L. Kaufman, Siraj M. Ali, Jeffrey S. Ross, Eileen White, Gyan Bhanot, Shridar Ganesan - JNCI Journal of the National Cancer Institute 2017 cited by 215

  21. Pan-cancer Analysis of Homologous Recombination Repair–associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score

    Authors: C. Benedikt Westphalen, Alexander D. Fine, Fabrice André, Shridar Ganesan, Volker Heinemann, Etienne Rouleau, Clare Turnbull, Luis Garcia Palacios, Jorge-Antonio Lopez, Ethan S. Sokol, Joaquin Mateo - Clinical Cancer Research 2021 cited by 80

  22. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity

    Authors: Ethan S. Sokol, Dean C. Pavlick, Hossein Khiabanian, Garrett M. Frampton, Jeffrey S. Ross, Jeffrey P. Gregg, Primo N. Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi, Vincent A. Miller, Brian M. Alexander, Siraj M. Ali, Shridar Ganesan, Jon Chung - JCO Precision Oncology 2020 cited by 181

  23. Computerized Image-Based Detection and Grading of Lymphocytic Infiltration in HER2+ Breast Cancer Histopathology

    Authors: Ajay Basavanhally, Shridar Ganesan, Shannon Agner, James Monaco, Michael D. Feldman, John Tomaszewski, Gyan Bhanot, Anant Madabhushi - IEEE Transactions on Biomedical Engineering, IEEE Trans. Biomed. Eng. 2009 cited by 267

  24. DNA hypomethylation promotes transposable element expression and activation of immune signaling in renal cell cancer

    Authors: Aguirre A. de Cubas, William Dunker, Andrew Zaninovich, Rachel A. Hongo, Anuj Bhatia, Anshuman Panda, Kathryn E. Beckermann, Gyan Bhanot, Shridar Ganesan, John Karijolich, W. Kimryn Rathmell - JCI Insight 2020 cited by 67